Research programme: anti-cancer mRNA therapeutics - Onkaido TherapeuticsAlternative Names: MT 004; MT-377; MT-380; MT-513
Latest Information Update: 27 Jan 2014
At a glance
- Originator Moderna Therapeutics
- Developer Onkaido Therapeutics
- Class RNA
- Mechanism of Action Protein synthesis stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 14 Jan 2014 Preclinical trials in Cancer in USA (Parenteral)